The Community Focus Channel on VJHemOnc is an independent medical education platform, supported with funding from Johnson & Johnson (Gold). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The Non-Malignant Channel on VJHemOnc is an independent medical education platform, supported with funding from Agios (Gold). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
IPIG 2025 | Choosing between crovalimab and eculizumab for patients with PNH
Catherine Flynn, MD, St James’s Hospital, Dublin, Ireland, briefly comments on the differences between crovalimab and eculizumab for paroxysmal nocturnal hemoglobinuria (PNH), highlighting that patient preference will often guide selection between these agents. While the agents are similar in efficacy, the decreased dosing frequency and subcutaneous route of administration of crovalimab make it a more convenient therapeutic option for patients. This interview took place at the 2nd International PNH Interest Group (IPIG) Conference in Paris, France.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved
Transcript
Often, it will be patients that might lead you. The drugs in themselves are probably quite similar, however, it would appear that the dose adjustment based on weight likely is a benefit to the patients. But for patients this is a game changer in terms of the fact that it can be self-administered at home without the supervision of a nurse coming to their home at times which may or may not suit...
Often, it will be patients that might lead you. The drugs in themselves are probably quite similar, however, it would appear that the dose adjustment based on weight likely is a benefit to the patients. But for patients this is a game changer in terms of the fact that it can be self-administered at home without the supervision of a nurse coming to their home at times which may or may not suit. So the fact that there’s a longer interval between the doses, eculizumab is given every two weeks, crovalimab is given every four weeks, so the dose interval change is very significant, and the fact that patients could self-administer as they move through the trial. So we had two patients on this trial, and while it hasn’t made a massive difference in terms of their hemoglobin or breakthrough events, it has allowed them to be at home for some of their treatments.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
Disclosures
CF is a PI on the COMMODORE trials.
